Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
ÌÇÐÄ´«Ã½
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. Daver, N., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R. A., Asch, A., Mannis, G. N., Chai-Ho, W., Tanaka, T. N., Bradley, T. J., Jeyakumar, D., Wang, E. S., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J. F., Sallman, D. LIPPINCOTT WILLIAMS & WILKINS. 2022View details for